Chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in hematological malignancies but remains largely ineffective in solid tumors. Accumulating evidence indicates that this limitation reflects not only suboptimal antigen recognition ... ...

请注册登录后继续浏览